Follow‐up strategies for patients treated for non‐metastatic colorectal cancer - Jeffery, M - 2019
| Cochrane Library Skip to Content Cookies Our site uses cookies to improve your experience …

Background Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males
and the second in females with a progressive increase in prevalence in industrialized …

Background In the KEYNOTE-177 study, pembrolizumab monotherapy provided statistically
significant and clinically meaningful improvements in progression-free survival versus …

Background Treatment of locally advanced rectal cancer with chemoradiotherapy, surgery,
and adjuvant chemotherapy controls local disease, but distant metastases remain common …

Background Radical surgery via total mesorectal excision might not be the optimal first-line
treatment for early-stage rectal cancer. An organ-preserving strategy with selective total …

Background Abdominoperineal resection is the standard treatment for patients with distal T2
or T3 rectal cancers; however, the procedure is extensive and mutilating, and alternative …

Background Knowledge about the efficacy of behavioural intervention technologies that can
be used by cancer survivors independently from a health-care provider is scarce. We aimed …

Backround The number of cancer survivors is growing steadily and increasingly, clinical
trials are being designed to include long-term follow-up to assess not only survival, but also …

Background We investigated very long-term bowel function after total mesorectal excision
(TME) with or without preoperative short-course radiotherapy (PRT) for rectal cancer, the risk …

Background Transanal total mesorectal excision (TaTME) has rapidly become an important
component of the treatment of rectal cancer surgery. Cohort studies have shown feasibility …